Primary completion· ClinicalTrials.gov
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohe
BI 3802876 History and Updates
7 events · 2023 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
7
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-11Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for BI 3802876 since 2023, drawn from openFDA, ClinicalTrials.gov, and PubMed.
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohe
Past events
2026
Trial started· ClinicalTrials.gov
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohe
Trial registered· ClinicalTrials.gov
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohe
2025
Primary completion· ClinicalTrials.gov
A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated
2023
Trial started· ClinicalTrials.gov
A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated
Trial registered· ClinicalTrials.gov
A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.